Chemo basic Flashcards

0
Q

Gompertzian tumor growth

A

pattern of exponential growth with exponential growth retardation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

What are the 3 cell growth types?

A

1) Static – neurons, striated muscle, oocytes
2) Expanding (normally quiescent except under stress/injury a proliferative burst is followed by return to quiescence)- hepatocytes, bile duct epithelium, vascular endothelium
3) Renewing (continuous proliferation) – bone marrow, epithelium, GI epithelium, sperm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Tumor doubling curve

A

-As tumor mass increases the time to double the tumor volume decreases.
-At later stages of tumor growth a small # of doublings produce a marked change in tumor size w/ increased potential for adverse clinical consequences.
-In general metastases have faster doubling times than their corresponding primary lesions.
Average doubling time for human cancers is 50 days.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

1 cm mass ~ X number of doubling

A

30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Growth Fraction

A

The proportion of tumor cells that are actively cycling.
Usually those cells near small blood vessels.
Variable by tumor type – 25-95%
Cell loss in tumors is high…70-95%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

First order Cell Kill Kinetics

A

A constant fraction of exposed cells are killed, rather than a constant number.
For curative chemotherapy, log cell kill (% of cells killed each cycle) must be very large (>99%) and repetitive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cure or prolonged survival achieved when…

A

cell pop reduced to 10 ^1 and 10^ 4 (not clinically detectable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hepatic metabolism (ICE VAT)

If you don’t take the liver into account, you’ll need an ice vat

A
  • Vinca alkaloids (vincristine, vinblastine, vinorelbine)
  • Ifos, Cytoxan, etoposide (hepatically metabolized, renally cleared)
  • Taxanes (Taxol, Taxotere)
  • Anthracycylines (doxil, doxorubicin)
  • VEGF inhibitors (cleared)
  • dose reduce MTX bc can cause hepatic fibrosis (Renault cleared)
  • 5 FU
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Renal clearance (Top BMI Promotes Cancer)

A
Platinums
Bleomycin
MTX
Topotecan
Ifos
Cytoxan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Alkylating agents (contain + charged alkyl groups that bind neg charged DNA)

A
  • Direct DNA damage (X-link, free radical, strand breakage) G1, S, G2 arrest
  • RT, platinum
  • Nitrogen mustards(cytoxan, ifos, melphalan)
  • Temodar
  • Bleomycin (not exactly alkylating agent, produces ROS-> DNA breaks)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Antimetabolites

A
  • Inhibition of nucleotide synthesis. G1, S arrest

- Antifolates(MTX, pemextred), nucleoside analogs (5FU, gemzar), hydroxyurea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Microtubule

A

M arrest
Taxanes (taxol, doxetaxol) promote tubulin polymerization
Vinka alkaloid inhibit polymerization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Topoisomerases

A
  • Topo II inhibitors :anthracyclines (doxorubicin, doxil),etoposide, actinomysin D
  • Topo I inhibitors: Topotecan
  • S phase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Signal transduction

A
  • Growth factor blockade: Trastuzumab, cetuximab, bevicizumab, pertuzumab
  • Inhibition of Tyr kinase signal transduction: erlotinib, gefitinib, imitanib, sorafenib, sunitinib, lopatinib
  • Hormonal inhibition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

RECIST = Response Evaluation Criteria in Solid Tumors

A

At least one 2cm (one dimension) target lesion
Other non target lesions
CR – disappearance of all target & nontarget
PR – disappearance of all target, without progression of nontarget & no new, at least 30% decrease in sum LD
PD – 20 % increase sum LD of targets
SD – BTWN PR and PD
CR: complete response, PR: partial response, LD: longest diameter, PD: progressive disease, SD: stable disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bone Marrow Toxicity

A
  • Neutropenia #1 manifesting 7-14 days from tx, lasting 3-10 days
  • RT, alkylating agents,DNA damaging agents (nitrosoureas, mitomycin C) can have cumulative effects
16
Q

Emetogenicity

A

High: Cisplatin, carboplatin, Cytoxan, dactinomycin
Low: Bleomycin, taxanes, vinca alkaloids, 5FU, MTX, doxil, gemzar, topotecan

17
Q

Which chemotherapies cause Alopecia?

TEA CUP

A

Worst: Taxanes, doxorubicin/doxil, IV etoposide
Possible: platinums, Cytoxan, 5FU

18
Q

Which chemotherapies cause Neurotoxicity?

A

Cisplatin*, taxanes, hexalen,

-cisplatin sx’s come on later and continue after stopping tx

19
Q

What dugs cause PPE?

A

Oral etoposide, 5 FU, Doxil, bleomycin, docetaxel, MTX

FU Doxil Making Beautiful Toes Erythematous

20
Q

Which chemotherapies are vesicants (can cause extravasion necrosis)?

A

Doxorubicin, dactinomycin, Taxotere, vincristine, mitomycin C

21
Q

Genitourinary complication of chemotherapy

A
  • Cisplatin: AKI if UOP not maintained. Mg and K loss known

- Hemorrhagic cystitis: Ifos-use mesna to bind acrolein. Can also happen with cytoxan

22
Q

What EXACTLY is cremephor??

A
  • Carrier of paclitaxel

- Mixture of polyoxyethylated castor oil and dehydrated alcohol (leads to mast cell degranulation and clinical HSR)

23
Q

Timing of hypersensitivity reactions

A
  • Platinum: second cycle of second course (~eighth)

- Taxol: 1st or 2nd cycle

24
Treatment of hypersensitivity reactions
- Platinum - **** - Taxol
25
What are the 3 phases of clinical trials?
- Phase 1: determine max tolerated dose & dose limiting toxicity - Phase 2: determine efficacy (e.g. RR) and toxicity. Done for a specific dx - Phase 3: RCT comparing new agent to standard therapy
26
How is body weight used in chemo?
- Actual: measured body weight - Adjusted (ABW) = ideal body weight (IBW) + 0.4(ABW - IBW). Used for obese patients (e.g BMI >25) - ASCO recommends using ACTUAL - GOG calculator uses adjusted
27
Infertility
- High risk: cytoxan, ifos, melphalan - Medium risk: cisplatin, doxorubicin - Low risk: MTX, 5FU, bleomycin, vincristine, dactinomycin - taxane risk unclear due to limited studies - should wait 6months after chemo to try to get preg - ovarian suppression effectiveness controversial Whole abdominal or pelvic radiation doses > 6 Gy in adult > 15 Gy in pre-pubertal girls > 10 Gy in post -pubertal girls Ref: American Cancer Society and Breast Cancer.org
28
What is an AUC?
- AUC: the area under the curve is a plot of concentration of drug in plasma against time. (correlates with anti-tumor activity) - The amount eliminated by the body = clearance (volume/time) * AUC (mass*time/volume). - Calvert Formula: Carboplatin dose (mg) = (Target AUC) x (GFR + 25) -GFR about equivalent to the estimated creatinine clearance (Ccr). Calculated with Cockcroft-Gault: Ccr (ml/min) = ([140 - Age(years)] x Weight (kg) x 0.85) /72 x Serum Creatinine (mg/dl)
29
platinum drugs
Gain access to intracellular compartment by passive diffusion and carrier mediated uptake; resistance MOA include increased efflux, reduced influx, intracellular detoxification by glutathione and metallothionenines, changes in DNA repair, defective apoptosis
30
Goldie Coldman hypothesis
treatment should begin as soon as possible to treat the smallers amt of bulk; multiple non cross resistant agents should be used to avoid selection of resistant clones; use drugs often and at highest possible doses
31
mechanisms of chemotherapy resistance
alteration of drug movement across cell membrane; increased DNA repair, defective apoptosis ; alterations of drug targets
32
Prodrugs
``` o Hexamethylamine (liver demethylation) o Cyclophosphamide (liver P450) o Xeloda(capecitabine) gets transformed to 5-FU (cells via dihydropyrimidine reductase) o Gemzar (cells via deoxycitidine kinase) o Ifos (liver microsomal enzymes) o Irinotecan (liver to active SN-38) o Mitoycin (reduction to alkylating agent) ```
33
Chemo dosing adjustments
- Cr capped w/ carbo for < 0.7?